Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

CRISPR powers everything from gene editing to rapid diagnostics, but how did one of its most versatile branches arise? A new Cell study, “Functional RNA splitting drove the evolutionary emergence of ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...